Merge PACS vs EchoNext

Merge PACS emphasizes intuitive workflows, customizable worklists, and features designed to reduce clicks and improve navigation for radiologists. Recent updates specifically address user feedback for faster and more intuitive diagnostic reading, including synchronized priors scrolling for mammography and real-time study updates in the viewer. EchoNext is deployed through the OpenEvidence platform, which aims for broad access, but specific details on its direct user interface and workflow within that platform are less detailed than Merge PACS's dedicated efforts to optimize the reading experience.

EchoNext is an FDA-cleared AI tool specifically designed to detect hidden structural heart disease from standard ECGs, including heart failure, valve disease, and pulmonary hypertension. Studies have shown it outperforms cardiologists in identifying these conditions and has led to earlier diagnoses and interventions, including the first reported AI-triggered heart transplant. Merge PACS offers AI integration, allowing access to third-party AI applications within its workflow, but its core clinical value lies in streamlining imaging data management and diagnostic interpretation across multiple modalities, rather than a specific, validated AI diagnostic capability like EchoNext.

EchoNext offers transparent tiered pricing starting at $600/month, with clear details on implementation fees and annual discounts. This transparency allows potential customers to better assess the value proposition. Merge PACS requires contacting the vendor for pricing details, which can make it more challenging to evaluate its cost-effectiveness upfront.

Merge PACS is an enterprise-level PACS designed for multi-site health systems, offering flexible deployment options (on-premise, cloud, hybrid) and extensive integration capabilities with EMR/EHR, RIS, HIS, and VNA systems. It focuses on enterprise-wide image management, consolidation, and workflow orchestration. EchoNext is available through the OpenEvidence platform and targets broad access, but its enterprise-level deployment and integration capabilities are not as extensively detailed as Merge PACS.

Merge PACS demonstrates innovation through its cloud-ready architecture, AI integration and orchestration capabilities, and continuous enhancements to diagnostic workflows based on user feedback. EchoNext represents a significant innovation as the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a capability previously not possible with ECGs alone. Both tools show strong innovation in their respective domains.

Merative provides comprehensive support for Merge PACS, including a community hub, phone support, webinars, and detailed DICOM conformance statements. The company also emphasizes customer-driven innovation and responsiveness to client feedback. While EchoNext is deployed via OpenEvidence, and Pathway Labs is expanding, specific details regarding their direct support and documentation for end-users are not as readily available as for Merge PACS.